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6-O-Nucleotidyltransferase: an aminoglycoside-
modifying enzyme specific for streptomycin/
streptidine†
Montserrat Latorre, Julia Revuelta, Eduardo García-Junceda* and Agatha Bastida*
Aminoglycosides are especially useful for the treatment of hospital-acquired infections. The main problem
for the application of these antibiotics is the presence of bacterial resistance enzymes, in particular,
nucleotidyltransferases (ANTs). These enzymes catalyze the transfer of an adenylyl group from the MgATP
complex to different positions of the antibiotic. To understand the mechanisms that lead to antibiotic inac-
tivation, we have performed a comprehensive experimental analysis of one of those enzymes. The 6-O-
nucleotidyltransferase enzyme (ANT(6)) from Bacillus subtilis was cloned, overexpressed and purified in E.
coli. The kinetic parameters revealed a narrow specificity of the ANT(6) for MgATP/streptomycin as sub-
strates. The binding epitope of the streptomycin recognized by the ANT(6) is the streptidine moiety. There-
fore, the use of streptidine as a “decoy acceptor” allows the recovery of the antibiotic activity of strepto-
mycin E. coli cells that are overexpressing the ANT(6).
Introduction
Aminoglycoside antibiotics are of special interest in medicine
for the treatment of severe bacterial infections.1–3 These anti-
biotics are active against either Gram + or Gram − bacteria,
since their primary mechanism of action is the inhibition of
bacterial protein synthesis by binding to the tRNA acceptor A
site in the small ribosomal subunit that is causing a misread-
ing and/or hindering the translocation step.4–8 For most of
the aminoglycosides, the aminocyclitol moiety is a
2-deoxystreptamine ring (2-DOS) and can be substituted at
positions 4 and 6 (kanamycin family 3) or at 4 and 5 (neomy-
cin 2 family). However, a number of active aminoglycosides
are structurally atypical, such as streptomycin (ST) 1 (Fig. 1).
The emergence of bacterial resistance for all classes of
antipathogenic agents has become a serious problem over
recent years.9–11 Aminoglycosides were one of the first groups
of antibiotics to meet the challenge of resistance.12 The most
prevalent source of clinically relevant resistance to amino-
glycoside antibiotics is conferred by the enzymatic inactiva-
tion of the drugs by the aminoglycoside-modifying enzymes
(AMEs).13,14
The AMEs can be classified as N-acetyltransferases (AACs),
O-adenyltransferases (ANTs) or O-phosphotransferases
(APHs). In each of these families, there are several enzymes
that catalyzed the reactions with different regioselectivities
and substrate specificities.
The ANT' family is the smallest of the three groups with
only a few enzymes identified to date [ANT(6)], [ANT(9)],
[ANTĲ4′)] and [ANTĲ2″)].15–18 One of the most prevalent ANT
enzymes is the streptomycin adenylyltransferase (ANT
(6)).19–21 This enzyme catalyzes the transfer of an adenyl
group from the [MgATP]− complex to the OH at the 6
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Fig. 1 Structures of aminoglycoside antibiotics: streptomycin (1),
neomycin (2) and kanamycin A (3).
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position of streptidine unit in the streptomycin (1), thus lead-
ing to a sharp decrease in the drug's affinity for its RNA tar-
get (Scheme 1). Streptomycin (1) was the first aminoglycoside
antibiotic to be discovered in 1943. It has a three-ring struc-
ture (Scheme 1), comprising a substituted aminocyclitol
(streptidine moiety), linked to a modified ribose (α-L-
streptose), which is linked in turn to an N-methyl-α-L-
glucosamine residue.
Some years ago, our group reported that the binding epi-
tope of the streptomycin recognized by this enzyme was the
streptidine moiety22 we also noted its use as a “decoy accep-
tor”‡23,24 by the ANT(6) enzyme to rescue the antibiotic activ-
ity of streptomycin (1) from bacterial strains overexpressing
this aminoglycoside-modifying enzyme. We showed that the
streptidine was a substrate for the aminoglycoside-
inactivating enzyme ANT(6), competing with the streptomycin
(1) for the active center of the enzyme. Thus, the addition of
this molecule in a cell culture restored the activity of the
streptomycin antibiotic normally rendered inactive by the
ANT(6) enzyme, because the streptidine was acting as a
“decoy acceptor” of the ANT(6).
Therefore, we demonstrated that the use of decoy accep-
tors can be an effective strategy for combating the phenome-
non of resistance promoted by AMEs. However, for the design
of more efficient decoy acceptors, a deeper knowledge of the
molecular mechanism of the AMEs, their structures and
interactions with the drugs is needed. Herein, we report the
biochemical characterization of the ANT(6) from Bacillus
subtilis. To this end and we cloned, overexpressed the enzyme
in E. coli. The kinetic parameters revealed a narrow specificity
of the ANT(6) for MgATP/streptomycin as substrates. Finally,
we assayed the use of 2-deoxystreptamine as a decoy acceptor,
and its ability to restore the antibiotic activity of streptomycin
against resistant bacterial strains.
Results and discussion
Cloning, over-expression, purification and characterization of
ANT(6)
The aadK gene from B. subtilis was amplified by PCR, using
primers designed specifically to complement 15 bp at the 5′
ends of codifying and complementary DNA strains. The rec-
ognition sequence for the restriction enzymes EcoRI and
HindIII was introduced in the amplification product during
the PCR process. The double-digested PCR product was
cloned into the vector pET-28b(+) to yield the recombinant
plasmid pET-aadk NHis6-tag.
The aadK gene was expressed in E. coli BL21(DE3) at 30
°C. SDS-PAGE analysis of the gene expression showed an
IPTG-inducible protein of 37.4 kDa of the ANT(6) with an
NHis6-tag. After addition of the thrombin enzyme, the
ANTĲ6)ΔHis enzyme was obtained with 35.5 kDa of weight
(Fig. S1†). The two-step purification of the ANT(6) yielded
well over 40 mg of protein per liter of the cell culture, with a
purity degree of at least 95% (Fig. S1†). The ANT(6) was
aggregated without MgCl2, so the use of that cation is essen-
tial to avoid the formation of aggregations (Fig. S2a†). The
purified ANTĲ6)ΔHis is a dimer based on an ultracentrifuga-
tion experiment (Fig. S2b†) and its mobility over Superdex
200 in standardized analytical-gel filtration experiments.
The activity of the pure recombinant enzyme was followed
by HPLC and reaction products identified by 1H-NMR.25 The
recombinant ANT(6) exhibited activity between pH 6.5 and
pH 8.5, with the maximum activity at pH 7.5. At pH values
over 7.5, the activity level drops drastically to virtually zero
(Fig. S3†).
Regarding the secondary structure of the recombinant
enzyme, the far-UV CD spectrum of purified ANT(6) shows
two minima in ellipticity at ~210 and ~222 nm, indicative of
a main α-helical secondary structure (Fig. 2a). The percent-
ages of the different secondary structure elements were esti-
mated using the CDPro26 software package ~48.2% α-helix,
~8.7% β-sheet, ~15.9% turns, and ~27.3% of unordered struc-
ture were thereby obtained. The tertiary structure of the pro-
tein in the microenvironment of the protein fluorophores
was analyzed using fluorescence-emission spectroscopy of 19
tyrosines and 7 tryptophan present in the ANT(6) sequence
(Fig. 2b). After excitation at 275 nm, the fluorescence spec-
trum exhibited an emission maximum centered at 345 nm,
close to the expected emission of free tryptophans exposed to
an aqueous solution (348–350 nm). The emission spectrum
obtained upon excitation at 295 nm, was almost identical to
the previous spectrum, indicating an almost negligible contri-
bution of tyrosines to the fluorescence spectrum of the
recombinant ANT(6) enzyme (Fig. 2b).
Scheme 1 ANT(6) catalyzes the adenylation of streptidine moiety (red)
in streptomycin (1) antibiotic, giving AMP-streptomycin inactive.
‡ The term “decoy acceptors” was introduced by M. Okayama, et al.23 and N. B.
Schwartz24 to designate those compounds, that being substrates for a particular
enzyme are able to inhibit a metabolic pathway, to distinguish them from inhib-
itors, which are compounds that block the enzyme without being modified by it.
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The thermal stability of the enzyme was initially assessed by
using CD spectroscopic analysis, in which the temperature
dependence of the dichroism signal at λ = 222 nm was moni-
tored (Fig. 3). The curve following the thermal unfolding of the
ANT(6) could be fitted to a simple thermodynamic unfolding
model. The melting temperature of the recombinant ANT(6)
was determined to be 56 ± 0.2 °C. The transition region was
sharp, thus indicating that the protein existed initially as a
compact, well-folded structure and that the unfolding reaction
was highly cooperative.
The influence of divalent cations in the activity and stability
of recombinant ANT(6)
The quaternary structure of the enzyme determined by sedimenta-
tion velocity experiments (Fig. S1a†) showed that the presence of
Mg2+ strongly affected the aggregation state of the enzyme. The
magnesium ion is by far the most frequently found metal ion
cofactor in enzymatic systems. This is most likely related to the
ability of Mg2+ to form stable complexes with ATP, which is nor-
mally associated with the metal ion when acting in a physiological
environment. On the other hand, Mn2+ is the required cofactor in
many other transferase enzymes, such as glycosyltransferases of
the Leloir patway.27 Therefore, we decided to study the influence
of Mg2+ or Mn2+ ion on the 2D-structure (Fig. 4).
The ANT(6) showed a similar activity in the presences of
MnCl2 and MgCl2 (0.07 and 0.08 U mg
−1, respectively) but was
much more stable in the presence of Mg2+ (Fig. 4). Concentra-
tions of MgCl2 above 20 mM promote a conformational
change of the protein that is reflected in the decrease of the peaks
≈195, ≈208 and ≈222 nm, which corresponds to an increase in
β-sheet structure of about 7% but which maintains a rela-
tively high degree of structure. However, manganese promotes a
higher loss of the protein's secondary structure. Thus, from a
concentration of 10 mM, the CD spectrum gives almost no sig-
nal indicating that the protein has lost its secondary structure
and, therefore, its chirality. This effect could be due to the
higher flexibility of Mn2+ ligand bonds in both length and angle,
which could promote the conformational change of the recom-
binant protein.28
Fig. 2 (a) Far-UV circular dichroism spectrum of ANT(6) in 5 mM Tris
buffer of pH 7.5; (b) fluorescence-emission spectrum of the ANT(6).
The solid line represents the spectrum obtained upon excitation at 275
nm. The dotted line represents the contribution of tyrosines to the
global spectrum.
Fig. 3 Thermal denaturation profile of the ANT(6) enzyme. Melting
temperature (Tm) was assessed using CD by following the temperature
dependence of the dichroism signal at 222 nm.
Fig. 4 CD spectra at 25 °C of the ANT(6) enzyme at different
concentrations of MgCl2 and MnCl2.
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ANTĲ6)-substrate specificity
The main kinetic parameters for ANT(6) from B. subtilis are
displayed in Table 1.
To the best of our knowledge, the kinetic parameters of only
three other ANTs have been described: the bifunctional enzyme
ANTĲ3″)-Ii/AACĲ6′)-IId from Serratia marcescens,28 the ANTĲ2″)-I
from Klebsiella pneumoniae29,30 and the ANTĲ4′) from S.
aureus.31,32 The ANTĲ3″)-Ii domain carried out the adenylation
of streptomycin with a higher catalytic efficiency (kcat/KM 3.2
105) than that of the ANT(6) from B. subtilis (Table 1). This
domain was highly specific for streptomycin; that is, it did not
adenylate 4,5- or 4,6-aminoglycosides, thus showing a similar
behaviour to that of the ANT(6). In the case of the ANTĲ2″)-I/
ANTĲ4′), its catalytic efficiency is similar to that of our enzyme
but it does not recognize streptomycin as an aminoglycoside.
In addition, we studied the effect of MgCl2 concentration on
the enzyme activity as a function of the relationship [MgCl2]/
[ATP]. The maximum activity was reached at a 17 mM concen-
tration of free Mg2+ (Fig. 5). Above this concentration, and with
a free-magnesium concentration of 37 mM, neither increased
activity nor an inhibitory effect was detected. The concentration
of magnesium required to reach maximum activity was higher
than that required to saturate the ATP. Some authors suggest
that this may be because the enzyme requires two molecules of
the divalent ion to carry out its activity: one that would bind to
the ATP and the other that would bind directly to the enzyme,15
which has been observed in the 3D-structure of ANTĲ4′)/
Kanamycin Complex (pdb 1kny).
We have already showed that streptidine is the minimum
moiety of streptomycin that is recognized by the enzyme and
that can be adenylated by the ANT(6) (Fig. S5†).22 In order to
study the ANT(6) specificity, the enzyme activity was tested
using different aminoglycosides, such as streptomycin, neomy-
cin, kanamycin, spectinomycin, ribostamycin, paromomycin,
neamine and the 2-deoxystreptamine (the common moiety of
the 4,5- and 4,6-aminoglycosides). The enzyme was highly spe-
cific for streptomycin (Table S1†) and did not recognize 4,5- or
4,6-aminoglycosides (no activity was detected with kanamycin
or ribostamycin). In fact, the enzyme only provides acceptor
groups for hydrogen-bond interactions with aminoglycoside
substrates. The abundance of acidic residues in the binding
pocket of the enzyme can be readily explained by reference to
the fact that aminoglycosides are invariably positively charged
molecules. The other ANT enzymes described, such as ANTĲ4′)
and ANTĲ2″), accept different aminoglycosides as substrates,
thus showing high rates of substrate promiscuity.31,32 This dif-
fering behavior can be explained by reference to the fact that, in
the former case, the natural substrates are 4,5 or 4,6-
aminoglycosides, both of which share the 2-deoxystreptamine
moiety (Fig. 1).
We have also studied the specificity of the nucleoside tri-
phosphate (ATP, GTP, CTP and UTP). The enzyme recognizes
the nucleotides with similar affinities25 but only showed activity
with ATP/GTP (Table S2†). According to these data, ANT(6)
shows a clear preference for nucleotide triphosphates incorpo-
rating purine aromatic systems. On the other hand, modifica-
tions of the inorganic fragment led to significant changes in
activity (Table S2†). Thus, replacement of a single oxygen atom
by a methylene group (ATP versus AMPCPP) and the suppres-
sion of the terminal γ-phosphate group (ATP versus ADP, AMP)
lead to a total loss of activity. Recent results obtained by our
research group have demonstrated that ANTĲ4′) from S. aureus
can employ inorganic triphosphate (P3) as a substrate to pro-
mote the regioselective phosphorylation of aminoglycosides.33
However, in the case of the ANT(6), no reaction of phosphoryla-
tion with streptomycin/P3 was detected.
In vivo activity of ANT(6)
Streptomycin is powerful antibiotic with minimal inhibitory
concentrations (MICs) of 5 μg ml−1 for E. coli BL21(DE3)
strain. However, when the ANT(6) enzyme is present, it lost
its antibiotic activity (MIC > 200 μg ml−1). On the other hand,
streptidine and 2-deoxystreptamine (2-DOS) (common moie-
ties of the streptomycin and 4,5- 4,6-aminoglycosides, respec-
tively) did not show any antibiotic activity in the absence of
ANT(6) (MIC >100 μg ml−1) (Table 2). In the case of 4,5-
aminoglycosides, binding to neomycin was detected but no
reaction was observed (Table S2†).25 As we have described,
the streptidine is a substrate of the ANT(6), so when it is
added together with streptomycin, it works as a “decoy accep-
tor”.22 With these previous results in mind, we assayed the
2-DOS34 as a “decoy acceptor” of the ANT(6) in the presence
of streptomycin. Meanwhile, streptidine is able to reduce the
MIC for streptomycine to 10 μg ml−1 when ANT(6) is
expressed, but 2-DOS did not show any affect (Table 2). This
Table 1 Kinetic parameters of the ANT(6) from B. subtilisa
Substrate KM (M) kcat (s
−1) kcat/KM (s
−1 M−1)
Streptomycin 3.8 × 10−5 0.03 9.2 × 102
ATPMg 8.4 × 10−5 0.018 2.1 × 102
Streptidine 6 × 10−4 0.0006 1.2
a 0.5 mM of streptomycin, 2 mM [ATPMgCl2], pH 7.5.
Fig. 5 The effect of the magnesium free-ion in the adenylated activity
of the streptomycin with the ANT(6).
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result could indicate that ANT(6) requires the presence of a
guanidine group in the aminocyclitol, since it is so specific
for streptomycin, unlike the other ANTs hitherto described.
This was verified because AMP-2-DOS product was not
detected by ESI-MS or HPLC.
Experimental
Materials
pET-28b(+) vector was obtained from Novagen. Taq DNA poly-
merase was purchased from Ecogen. T4 DNA ligase was obtained
from MBI Fermentas. Restriction enzymes EcoRI and HindIII
were purchased from Boehringer Manheim. Isopropyl-L-thio-β-D-
galactopyranoside (IPTG) was purchased from Applichem. E. coli
competent cells BL21 (DE3) was purchased from Stratagene Co.
(San Diego, CA). Kanamicyn, ATP and other aminoglycoside anti-
biotics were obtained from Sigma. Nickel-iminodiacetic acid
(Ni2+IDA) agarose was generous donated by ABT. Bacillus subtilis
was obtained from CECT.
Cloning, expression and purification the ANT(6)
PCR amplification was performed in a 100 μL reaction mix-
ture containing DNA (3 μL) of Bacillus subtilis as template,
water (70.5 μL), buffer (100 mm Tris-HCl, 500 mm KCl, pH
8.0, 10 μL), MgCl2 (2 mm), dNTPs (200 μm), primers (1 μm)
ANT6-Ct (5′cgaagctttcactttactgagcaataaa3′) and ANT6-Nt (5′
gccgcgaattccatgcgaagtgagcaggaaat3′) and Taq DNA polymer-
ase (2.5 U). The reaction was subjected to 25 cycles of ampli-
fication. The cycle conditions were set as follows: denatur-
ation at 94 °C for 1 min, annealing at 55 °C for 1.0 min, and
elongation at 72 °C for 1.5 min. The PCR product was intro-
duces into the pGem-T easy vector. The sequencing of the
DNA insert was carried out with the promotors T7 and SP6.
Then aadK insert was digested with EcoRI and HindIII
enzymes and inserted into the pET-28b(+) vector that the
resulting plasmid pET-ANT(6) was transformed into E. coli
strain BL21 (DE3) which then showed the expected resistance
pattern to the streptomycin.
The selected clone was grown up on 100 mL of LB
medium containing 26 μg mL−1 kanamycin at 37 °C with
shaking. When the cell growth reached an optical density at
600 nm (O.D.600) of 0.5, the temperature was switched to 30 °C
and the culture was induced with 0.5 mM IPTG. After 24
hours of induction the expression level was analysed by SDS-
PAGE using gels with 13% of polyacrylamide in the sepa-
ration zone. The culture broth was centrifuged (5000 × g, 20
min, 4 °C), and the cells were suspending in Tris buffer (8
mL g−1 cells, 50 mm pH 8.0) and was added EDTA (50 mm,
pH 8.2) and lysozyme (2 mg g−1 cells). The suspension was
gently stirred at room temperature during 1 hour, and the
suspension was kept at 4 °C overnight. The preparation was
gently sonicated for 40 s and cooled down in ice (4 times) to
decrease viscosity. DNase (10 μg g−1 cells) and MgCl2 (0.95 μg
mL−1 of preparation) were added, and the mixture was refrig-
erated for 20 min. The mixture was then centrifuged for 30
min at 13 000 × g to separate the soluble proteins from the
insoluble ones. To the soluble fraction 1% of streptomycin
was added and stirred for 20 min at 4 °C. Then the cell free
extract (CFE) was recovered by centrifugation.
1.5 mL of CFE was applied to 0.5 gr of Ni2+IDA-agarose,
previously equilibrated with phosphate buffer, pH 7.0. The
proteins non-specifically retained were washed with the same
buffer. ANT(6) was eluted with the same buffer containing
0.5 M of imidazole. After that, the solution was dialyzed
against phosphate buffer 5 mM, pH = 7.0. After this step, the
recombinant enzyme was found to be more than 90% pure as
assessed by SDS-polyacrylamide gel electrophoresis. Further
purification of the recombinant ANT(6) was accomplished by
size-exclusion chromatography on HiLoad 26/60 Superdex
200 PG column controlled using the AKTA-FPLC system. The
column was developed in 20 mM phosphate buffer pH 7.5
containing 0.15 M NaCl at a constant rate of 1 ml min−1.
Fractions showing activity were pooled and dialyzed with
water and concentrated by lyophilisation. Protein concentra-
tions were estimated by the Bio-Rad protein assay method
using bovine serum albumin as a standard.
Circular dichroism spectroscopy
Far-UV circular dichroism (CD) spectra were recorded in the
wavelength range of 195–240 nm using a Jasco J-810 spectro-
polarimeter equipped with a constant temperature cell holder
Jasco PTC423-S Peltier. The protein concentration was 5.3 μM
and the optical path length 0.1 cm. The contribution of the
buffer was always subtracted. For each sample, three spectra
were accumulated at a scan speed of 20 nm min−1 with a
bandwidth of 0.2 nm and averaged automatically. All spectra
were background-corrected, smoothed and transformed into
mean residue ellipticity (θ) in the JASCO spectra manager. A
value of 110 g mol−1 was used as a mean residue weight for
ANT(6).The secondary structure of the protein was evaluated
by computer fit of the dichroism spectrum into four simple
components (α-helix, β-sheet, turns and random coil) using
the CDPro software package containing three commonly used
programs: SELCON3, CONTIN/LL and CDSSTR.26
Ultracentrifugation
The quaternary structure of recombinant ANT(6) from B.
subtillis was assessed using sedimentation equilibrium
Table 2 In vivo activity of streptomycin and neomycin alone or in combi-
nation with streptidine against E. coli strains expressing or not the ANT(6)
Amynoglycoside E. coli
MICa E. coli
(pET)
E. coli
pET-aadk
Streptomycinb 5 5 >200
Streptidine >100 >100 >200
Streptomycin + streptidineb 5 5 10
2-DOSc >100 >100 >100
Streptomycin + 2-DOS 2 100 100
a MIC: minimum inhibitory concentration, values (μg mL−1). b Data
taken from reference.22 c 2-DOS (2-deoxystreptamine).
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experiments. These experiments were performed at the
Department of Chemical Physics of Biological Macromole-
cules of the IQFR-CSIC. The initial concentration of the pro-
tein used in these experiments was 0.96 mg mL−1.
Fluorescence experiments
The experiments were conducted on Perkin Elmer LS50B lumi-
nescence spectrometer with the program FLWin. A quartz cell
with a 1 cm path length in both the excitation (275 nm and 295
nm) and emission (295 to 400 nm) directions was used in all
the experiments that were performed at 25 °C. The ANTĲ6) pro-
tein concentration was 30 μM in phosphate buffer 5 mM, pH =
7.5. The spectres were normalized by origin 7.0 program.
Measurement of enzyme activity
The activity of the pure recombinant enzyme was follow by
HPLC and the identity of the adenylated products were con-
firmed by ESI-MS. The formation of the product was followed
by HPLC at 260 nm (Vydac column eluted with TFA pH 3.0
buffer). Enzyme concentration was calculated using a molar
absortion coefficient at 60 400 M−1 cm−1 at 280 nm. The reac-
tion mixture contained 50 mM Hepes buffer, pH (6.5–8),
nucleoside derivatives (3 mM), aminoglicoside (0–2.5 mM),
MgCl2 (0–35 mM) and the reaction were started by the addi-
tion of ANT(6) enzyme (0.5 μM) at room temperature in a vol-
ume of 1 ml.
Minimal inhibitory concentrations (MIC)
The different strains were grown in 1 ml tubes and Mueller–
Hinton broth to an optical density OD600 of 0.4 units, then
ANT(6) was expressed by induction with 0.5 mM of IPTG until
0D600 0.6 when. Then, the desired concentrations of antibiotics
were added from stock solutions. The samples were incubated
at 37 °C for 12 h, when the control culture (with no antibiotic)
had an OD600 of 1.2–1.6. The OD600 of each sample was read
and the MIC was taken as the lowest antibiotic concentration
inhibiting bacterial growth greater than 90%.
Conclusions
In conclusion, we have described the overexpression and bio-
chemical characterization of the ANT (6) from B. subtilis. The
results reported throughout this manuscript highlight the
high specificity of the ANT(6) for streptomycin-ATP/GTP-Mg
of an enzyme that is involved in bacterial resistance against
aminoglycoside antibiotics.
From a medicinal chemistry perspective, the combination of
the features present in the ANT(6) give the enzyme a narrow tol-
erance to chemical variations in the aminoglycoside/nucleotide,
making it very useful in the design of non-inactivable derivatives
in order to avoid bacterial resistance. Moreover, the design of
new inhibitors or decoy acceptors for this enzyme must
considerer the minimum unit of streptidine that is essential,
and the fact that only nucleotide derivatives of purine bases will
be recognized.
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